Senior Management Team

Solomon S. Steiner, PhD, Executive Chairman

Dr. Steiner founded and served as CEO to three publicly-traded drug-delivery companies: Biodel Inc. (Nasdaq: BIOD), MannKind Corp. (Nasdaq: MNKD), and Emisphere Technologies, Inc. (OTCQB: EMIS). Dr. Steiner served as Biodel’s Chairman, President and Chief Executive Officer from its inception in December 2003 through March of 2010. In 1991, Dr. Steiner founded Pharmaceutical Discovery Corporation ("PDC"), a biopharmaceutical corporation and is an inventor of its Technosphere™ Technology and MedTone™ Inhaler. Dr. Steiner served as PDC’s Chief Executive Officer and Chairman of the board of directors from its inception until December 2001, when PDC was merged with two other companies to form MannKind Corporation. From December 2001 to February 2003, Dr. Steiner served on MannKind’s board of directors and as a Corporate Vice President and Chief Scientific Officer. In 1985, Dr. Steiner founded and was Chairman of the board and President of Clinical Technologies Associates, Inc. ("CTAI"), now known as Emisphere Technologies, Inc. Under his leadership CTAI went public in February of 1989. Dr. Steiner is an inventor of Emisphere’s oral delivery technology for peptides and mucopolysaccharides.

 

Dr. Steiner is a Full Professor Emeritus at City University of New York, New York Medical College, a Research Full Professor of Psychiatry and Neurology at New York University School of Medicine and Adjunct Full Professor of Medical Science at Brown University.

 

Dr. Steiner serves as a member of the Board of Directors of the American Journal of Hypertension. Dr. Steiner was elected a Fellow of the American Psychological Association in 1973 for his work in psychopharmacology and has authored or co‑authored over 200 scientific publications. Dr. Steiner has served as a consultant to numerous pharmaceutical companies in connection with drug discovery and clinical efficacy testing. From 1966 till 1970 he was a Senior Research Scientist at Schering-Plough Corp. where he and his colleagues discovered and developed the first dopamine-2 receptor blockers. From 1964 to 1966 Dr. Steiner served as a Captain, Division of Neuropsychiatry, Walter Reed Army Institute of Research, U.S. Army. Dr. Steiner recieved a BA from New York University with a major in psychology and chemistry and a PhD from New York University.

Bryan E. Laulicht, PhD, President, Chief Executive Officer
Dr. Laulicht was previously a Postdoctoral Fellow in the Harvard-MIT Health Sciences Technology program in the laboratories of Dr. Robert Langer and Dr. Jeffrey Karp. In 2012 he was named one of the 35 most innovative people under the age of 35 by MIT Technology Review.

 

Dr. Laulicht has co-authored eleven publications and 18 patents; his work has been published in nine conference proceedings and abstracts. Dr. Laulicht received a BA in Biophysics from Columbia University where he was an I.I. Rabi Science Research Scholar and a PhD in Medical Science from Brown University, conducting research in Dr. Mathiowitz's laboratory, for which he won the Joukowsky Outstanding Dissertation Award.

Loni da Silva MS, RAC, Vice President, Regulatory Affairs

Ms. da Silva has over thirty years of regulatory affairs, clinical research, and drug development with big pharma and small start-ups. Ms. da Silva has worked in a variety of therapeutic areas such as ophthalmology, virology, oncology, cardiovascular, anti-infectives, pain, hematology and gastrointestinal diseases. Ms. da Silva received a B.S. in Microbiology from Pennsylvania State University, a Masters in Drug Regulatory Affairs from Long Island University and is regulatory affairs certified.

Raymond R. Mandra, JD, Patent Counsel
Mr. Mandra is a former partner of the intellectual property law firm of Fitzpatrick, Cella, Harper & Scinto, where he practiced for 28 years out of their New York office. He was also chair of the firm’s biotechnology group for more than a decade. Representative clients of Mr. Mandra, while in private practice, included Allergan PLC, Astellas Pharma Inc., Bristol-Myers Squibb, Genzyme, Leo Pharma Inc., Mars Incorporated, Novartis, Pfizer, Sanofi and Warner Chilcott. Prior to entering the private practice of law, Mr. Mandra worked for nine years as a chemist for the General Foods Corporation. Mr. Mandra received his J.D., magna cum laude in 1990 from Pace University School of Law, where he was the Research and Writing Editor on the Pace Law Review. He also has an M.S. in Chemistry from Long Island University and a B.S. in Chemistry from the State University of New York at Oswego.
Philip N. Sussman, Executive Vice President of Finance, Treasurer, Chief Financial Officer

Mr. Sussman is Managing Partner of The Channel Group, LLC, served as a member of senior management (Head of Business Development, CFO, and CEO) of several public and private biotechnology companies, including Perlegen Sciences, Inc., Memory Pharmaceuticals Corp., and Cadus Pharmaceutical Corp. In these positions he established collaborations with major pharmaceutical companies, including AstraZeneca AB, Bristol-Myers Squibb Co., Eli Lilly & Co., GlaxoSmithKline plc, Pfizer Inc., Solvay Pharmaceuticals B.V., and Unilever plc that provided in aggregate more than $100 million in research funding and equity investments. His deal sheet lists 27 significant life sciences transactions, including an IPO on NASDAQ. He also initiated and was responsible for in-licensing of late-stage clinical and pre-clinical drug candidates. Prior to those positions, he was Director of Strategy & Business Development at Ciba-Geigy Corp.'s (now Novartis) Pharmaceuticals Division.


Mr. Sussman is on the Board of Directors of Thar Pharmaceuticals, Inc. and was a founder and member of the Board of Lesanne Life Sciences, LLC. He was a member of the Board of LCT BioPharma Inc., the U.S. subsidiary of Living Cell Technologies Limited (LCT: ASX). In addition, he previously served as a member of the Board of Directors and management of Phage Pharmaceuticals, Inc., a specialty biopharmaceutical manufacturer and developer of therapeutic proteins. Mr. Sussman has a BS in Physics from Stony Brook University, a Master of Science in Biotechnology from Manhattan College, and an SM in Management with a concentration in Finance from the Sloan School of Management, MIT.

Peter van Straelen, Executive Vice President, Business Development
Mr. van Straelen is the former President of U.S. Operations and Executive Vice President for Worldwide Sales and Marketing for Akzo Nobel N.V.’s business unit, Diosynth, the largest manufacturer of heparin for pharmaceutical use. He received an MSc in Biochemistry from the University of Amsterdam.